Kiniksa Pharmaceuticals International shares jumped 5.4% in the last trading session to close at $62.41, backed by heavy volume. The gain extends the stock's 22.4% advance over the past four weeks, driven by robust commercial performance of its flagship therapy Arcalyst, the first FDA-approved treatment for recurrent pericarditis in patients aged 12 and older. The company is also advancing its next-generation IL-1 pipeline, with phase II dose-finding data for KPL-387 expected in the second half of 2026 and a pivotal phase III study anticipated to begin by year-end. Another candidate, KPL-1161, is in preclinical development with a phase I trial expected by the end of 2026. Analysts expect Kiniksa to report quarterly earnings of 30 cents per share, a year-over-year increase of 30.4%, on revenues of $227.78 million, up 45.3%.
Kiniksa Pharmaceuticals LtdRobust commercial performance of Arcalyst, the first FDA-approved treatment for recurrent pericarditis, driving strong revenue growth.
Cartesian Therapeutics Inc.